SCHEMBL21422285

SCHEMBL21422285

CC(=O)NC(CC(N)=O)C(=O)NC(CC(N)=O)C(N)=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ECE1 P42892 4/20 0.53
GNPAT O15228 2/20 0.46
SIRT5 Q9NXA8 2/20 0.44
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
ALOX15 P16050 1/20 0.38
NFKB1 P19838 1/20 0.38
PTGS2 P35354 1/20 0.38
THPO P40225 1/20 0.38
RECQL P46063 1/20 0.38
BLM P54132 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALDH1A1 P00352 1/20 0.37
PDCD1LG2 Q9BQ51 1/20 0.35
CD274 Q9NZQ7 1/20 0.35
MMP8 P22894 1/20 0.35
ACE P12821 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM4 P08173 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15810863 0.92 ECE1 (0.50) ECE1GNPATSIRT5KDM4EMAPT
SCHEMBL12112082 0.92 ECE1 (0.50) ECE1GNPATSIRT5KDM4EMAPT
SCHEMBL7003664 0.92 ECE1 (0.50) ECE1GNPATSIRT5KDM4EMAPT
SCHEMBL13930092 0.90 SIRT5 (0.47) ECE1GNPATSIRT5CHRM2CHRM4
SCHEMBL13930086 0.90 ECE1 (0.44) ECE1GNPATSIRT5KDM4EMAPT
SCHEMBL13930091 0.88 ECE1 (0.47) ECE1GNPATSIRT5CHRM2CHRM4
SCHEMBL14499478 0.84 KDM4E (0.43) ECE1GNPATSIRT5KDM4EMAPT
SCHEMBL20244923 0.84 KDM4E (0.43) ECE1GNPATSIRT5KDM4EMAPT
SCHEMBL13637922 0.84 KDM4E (0.43) ECE1GNPATSIRT5KDM4EMAPT
SCHEMBL26019602 0.82 GNPAT (0.41) ECE1GNPATKDM4EMAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10787490-B2 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases Protaganist Therapeutics, Inc. (US) 2020-09-29 US disclosed
US-20190300590-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES PROTAGONIST THERAPEUTICS, INC. 2019-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190300590-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES IL23R, IL1RN, VIP ECE1 1266/4885GNPAT 4170/4885SIRT5 3860/4885
US-10787490-B2 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases IL23R, IL1RN, IL36G ECE1 978/4885GNPAT 4123/4885SIRT5 4232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.